Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.2443
+0.0065 (2.73%)
Jul 31, 2025, 3:59 PM EDT

Northwest Biotherapeutics Company Description

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer.

The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.

Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.

The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers.

Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics logo
CountryUnited States
Founded1996
IndustryBiotechnology
SectorHealthcare
Employees25
CEOLinda Powers

Contact Details

Address:
4800 Montgomery Lane
Bethesda, Delaware 20814
United States
Phone240 497 9024
Websitenwbio.com

Stock Details

Ticker SymbolNWBO
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
ISIN NumberUS66737P6007
SIC Code2836

Key Executives

NamePosition
Linda F. Powers J.D.Chairperson, Chief Executive Officer, President, Chief Financial Officer and Chief Accounting Officer
Dr. Alton L. Boynton Ph.D.Founder, Chief Scientific Officer, Secretary and Director
Dr. Marnix L. Bosch M.B.A., Ph.D.Chief Technical Officer
Leslie J. GoldmanSenior Vice President and General Counsel
David InnesVice President of Investor Relations